November 16, 2023 FDA Grants Orphan Drug Designation to EPI-321, Epicrispr Biotechnologies’ Novel Genetic Medicine Candidate for Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)
October 31, 2023 Kite and Epicrispr Biotechnologies Announce Collaboration to Develop New Cell Therapies for Cancer
October 26, 2023 Epicrispr Biotechnologies Reports New Data on Hypercompact Cas Proteins Optimized for Broad Therapeutic Applicability
October 19, 2023 Epicrispr Biotechnologies to Present at the Upcoming Annual European Society of Gene and Cell Therapy
October 17, 2023 Epicrispr Biotechnologies Announces the Appointment of Weston Miller, M.D., as Chief Medical Officer
October 5, 2023 Epicrispr Biotechnologies to Present at the Upcoming BMO Life Sciences Private Company Showcase
September 28, 2023 Epicrispr Biotechnologies to Present Preclinical Data at 28th International Annual Congress of the World Muscle Society
September 19, 2023 Epicrispr Biotechnologies to Present at Upcoming BMO Biopharma Spotlight Series Event
September 14, 2023 Epicrispr Biotechnologies Reports Discovery of Exceptionally Durable Gene Activators and Creation of Machine Learning Algorithm to Design New Activators
August 17, 2023 Epicrispr Biotechnologies Presents New Data on Epigenetic Editing Platform at CRISPR Frontiers Conference
